PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Podobne knjige/članki

• PTPN9 IS A NEGATIVE REGULATOR OF HER3 PHOSPHORYLATION AND A PROGNOSTIC BIOMARKER IN HER2 POSITIVE BREAST CANCER
  od: Gijsen, M, et al.
  Izdano: (2012)
• Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
  od: Negar Pourjamal, et al.
  Izdano: (2025-03-01)
• Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
  od: Alena Rudkouskaya, et al.
  Izdano: (2020-12-01)
• Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
  od: Gijsen, M, et al.
  Izdano: (2010)
• In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
  od: Sietske B.M. Gaykema, et al.
  Izdano: (2014-07-01)